With the threat of swine flu in 2009 came vaccine shortages, long lines at
distribution centers, and frustrated consumers. New technologies for
manufacturing flu vaccines could increase the speed and effi ciency of
producing vaccines and help to avoid these problems. The European Commission' s
approval of Novartis' s Optaflu in 2007 was a signifi cant step forward for
cell-based production methods, and many competitors are jumping into the race
to develop the next generation of influenza vaccines.
Questions Answered in This Report:
- Pandemic influenza threats and outbreaks have had a dramatic impact on the
overall influenza vaccine market. What fundamental changes to the dynamics
of the marketplace occurred as a result of the H5N1 avian influenza threat?
How did governments respond to the 2009 A/H1N1 pandemic? How did this outbreak
affect vaccine manufacturers?
- The manufacture of influenza vaccines is based on antiquated methods
initially developed in the 1940s. What new methods are being implemented to
increase the effi ciency and speed of manufacturing influenza vaccine? Which
companies are leading this trend?
- The drive to create new manufacturing methods is prompting innovative
development efforts throughout the industry. What cutting-edge technologies
are most advanced in development? Which companies are investing in and
developing these technologies?
- Collaboration among pharmaceutical companies and biotech companies as well
as government support and participation are key to accelerating the
development of new vaccine manufacturing technologies. Which companies are
involved in influenza-vaccine-related dealmaking? How is the U.S. government
promoting and supporting influenza vaccine development?
- Influenza disease and prevention: Occurrence and impact of seasonal
and pandemic influenza infections, emerging pandemics, the threat and impact
of the H5N1 avian flu virus.
- The 2009 A/H1N1 pandemic: Threat, spread, and results of 2009
A/H1N1 infections, government response, vaccine approvals.
- Impact of 2009 A/H1N1: Vaccine shortages and surpluses, fi nancial
impact on vaccine manufacturers, Decision Resources' Pharmaview historical
sales data and forecast for influenza vaccines.
- Egg-based manufacturing methods: Strain identifi cation, seed
production, production methods, drawbacks.
- Mammalian-cell-based methods: Production processes, cell lines,
Novartis, Baxter International, Solvay Pharmaceuticals, Crucell.
- Emerging technologies: Baculovirus production systems, recombinant
antigens, virus-like particles, toll-like-receptor-based platform, universal
vaccines, DNA vaccines, Protein Sciences, Novavax, VaxInnate, Dynavax, Vical.
- Outlook for influenza vaccine manufacturing: Impact of drawbacks on
current methods, promotion and development of cell-based methods, adjuvants,
Mentioned in This Report:
- Abbott Laboratories
- Antigen Express
- Avimex Laboratories
- Baxter International
- Bharat Biotech
- Biological E
- Cadila Pharmaceuticals
- CPL Biologicals
- CSL Biotherapies
- Dynavax Technologies
- DynPort Vaccine Company
- Eurocine Vaccines
- Folia Biotech
- GE Healthcare
- Generex Biotechnology
- ID Biomedical
- Immune Targeting Systems
- Inovio Biomedical
- Johnson & Johnson
- Juvaris BioTherapeutics
- MedImmune (AstraZeneca
- Merck & Co.
- Merieux Alliance
- Protein Sciences
- Sanofi Pasteur
- Sanofi -Aventis
- Select Vaccines
- Shantha Biotechnics
- Shenzen Neptunus Interlong
- Sinovac Biotech
- Solvay Biologicals
- Solvay Pharmaceuticals
- Theraclone Sciences
- UMN Pharma
- Vivaldi Biosciences
- Zhejiang Tianyuan
“Recent flu vaccine shortages brought the drawbacks of current production
methods into sharp relief. Suppliers need to act quickly to develop better
systems that can be scaled up rapidly enough to meet the demands of a
potentially virulent pandemic. Development of a universal flu vaccine would
revolutionize the fi eld.” -Barbara M. Bolten, M.S., M.B.A., Senior
Program Manager, Decision Resources.